NEW YORK (GenomeWeb News) – Fluidigm said this week it has completed its $207.5 million buy of mass cytometry firm DVS Sciences. Principally operating in Sunnyvale, Calif., DVS is now a wholly owned subsidiary of Fluidigm.
Registering provides access to this and other free content.
Already have an account?Login Now.
Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.
The New York Times reports that a number of companies and research institutes are pursuing gene therapies.
Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.
In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.